Stocks · Healthcare · Biotechnology
Agios Pharmaceuticals, Inc. AGIO
$31.25 -1.73% Close, Oct 5, 2026 · NASDAQ · Market cap $1.90B
Strong growth
Next earnings report: Oct 29, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $98.3M, up 140.6% from a year earlier, accelerating from 78.3% a quarter earlier.
- Diluted EPS over the last four quarters was $-7.01, down 163.4% year over year.
- Operating margin widened to -466.8% from -1129.1% a year earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 8%
- EPS growth (TTM, YoY)Bottom 14%
- Revenue growth, 3-year CAGRTop 12%
- Revenue growth accelerationTop 5%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 31%
- Gross marginTop 21%
- Operating marginBottom 17%
- Accruals (lower is better)Bottom 39%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 30%
- Free-cash-flow yieldBottom 26%
- EBITDA / enterprise valueBottom 26%
- Sales / enterprise valueBottom 22%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 26%
- 6-month returnBottom 31%
- 1-year return vs S&P 500Bottom 28%
- Distance from 52-week highBottom 49%
- Trend checklist (0–4)Top 43%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 48%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 49%
- Upside to consensus price targetBottom 39%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 24%
- Maximum drawdown, 3 yearsTop 40%
- Beta vs S&P 500 (lower is better)Bottom 17%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 78.3% | 140.6% | ↑ |
| EPS growth (YoY) | -164.2% | -163.4% | ↑ |
| Gross margin | 82.0% | 87.9% | ↑ |
| Operating margin | -1129.1% | -466.8% | ↑ |
| FCF margin | -1000.7% | -371.4% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 140.6% | 78.3% | ↑ | Top 8% |
| EPS growth (TTM, YoY) | -163.4% | -164.2% | ↑ | Bottom 14% |
| Gross margin | 87.9% | 82.0% | ↑ | Top 21% |
| Operating margin | -466.8% | -1129.1% | ↑ | Bottom 17% |
| Net margin | -418.2% | 1590.4% | ↓ | — |
| Free-cash-flow margin | -371.4% | -1000.7% | ↑ | — |
| Return on invested capital | -43.3% | — | Bottom 31% | |
| Revenue growth, 3-year CAGR | 56.0% | — | Top 12% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -4.6%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 59.0%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +162.8 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.37%
- Shareholder yield
- -0.37%
- Share count change, 1 year
- +2.7%
- Share count change, 3-year CAGR
- +2.3%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jul 30, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- +4.5%
- Average 2-day reaction, last 8
- +1.5%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $42.67
- Target vs current price
- +36.5%
- Analysts with a rating
- 29
- Share rating Buy or Strong Buy
- 76%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 30, 2026 | -2.4% | -6.5% | -9.4% | -2.9% | — |
| Apr 29, 2026 | +6.6% | +13.1% | +9.7% | +15.4% | +46.6% |
| Feb 12, 2026 | +6.1% | +1.3% | +3.1% | -0.4% | +0.3% |
| Oct 30, 2025 | +7.8% | +2.9% | -3.5% | -30.8% | -31.7% |
| Jul 31, 2025 | -10.9% | -0.9% | +0.5% | +4.6% | +12.1% |
| May 1, 2025 | +13.9% | +4.2% | -5.0% | +7.2% | +25.3% |
| Feb 13, 2025 | -3.0% | +1.5% | +2.9% | -5.3% | -16.7% |
| Oct 31, 2024 | +6.6% | -4.0% | +11.4% | +26.7% | -27.1% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | -$1.69 | -$1.65 | -2.4% | $44.7M |
| Apr 29, 2026 | -$1.69 | -$1.81 | +6.6% | $20.7M |
| Feb 12, 2026 | -$1.85 | -$1.97 | +6.1% | $20.0M |
| Oct 30, 2025 | -$1.78 | -$1.93 | +7.8% | $12.9M |
| Jul 31, 2025 | -$1.93 | -$1.74 | -10.9% | $12.5M |
| May 1, 2025 | -$1.55 | -$1.80 | +13.9% | $8.7M |
| Feb 13, 2025 | -$1.74 | -$1.69 | -3.0% | $10.7M |
| Oct 31, 2024 | $16.22 | $15.22 | +6.6% | $9.0M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 18.61× | — | — | Bottom 22% |
| Free-cash-flow yield | -19.24% | — | — | Bottom 26% |
| Earnings yield | -22.43% | — | — | Bottom 30% |
P/E over the past five years
Range 2.7× – 3.9× since Sep 30, 2024. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 44
- 50-day average slope (20 days)
- -6.5%
- 200-day average slope (20 days)
- +1.8%
- Distance from 50-day average
- -6.3%
- Distance from 200-day average
- +0.7%
- RSI (14)
- 37.3
- Relative volume
- 0.79×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 41.6%
- Volatility vs own 5-year history
- 29th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.88
- Correlation with S&P 500
- 0.42
- Current drawdown from 1-year high
- -31.3%
- Maximum drawdown, 3 years
- -63.8%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jun 21, 2021 | Jun 14, 2022 | -72.2% | 248 days | 624 days (Dec 6, 2024) |
| Dec 6, 2024 | Nov 19, 2025 | -63.8% | 238 days | Not yet recovered |
| Dec 1, 2020 | Dec 18, 2020 | -28.6% | 13 days | 12 days (Jan 7, 2021) |
| Feb 11, 2021 | Mar 3, 2021 | -19.8% | 13 days | 65 days (Jun 4, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.90B
- EPS, diluted (TTM)
- -$7.01
- Revenue (TTM)
- $98.3M
- 52-week range
- $22.24 – $46.00
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $14.2M | $26.8M | $36.5M | $54.0M |
| Gross profit | -$18.8M | $12.5M | $17.3M | $32.3M | $42.5M |
| Operating income | -$378.4M | -$389.0M | -$391.5M | -$425.7M | -$472.1M |
| Net income | $1.60B | -$231.8M | -$352.1M | $673.7M | -$412.8M |
| EPS (diluted) | -$6.36 | -$4.23 | -$6.33 | $11.64 | -$7.12 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.0M | $10.7M | $8.7M | $12.5M | $12.9M | $20.0M | $20.7M | $44.7M |
| Net income | $947.9M | -$96.5M | -$89.3M | -$112.0M | -$103.4M | -$108.0M | -$99.1M | -$100.7M |
| EPS (diluted) | $16.22 | -$1.69 | -$1.55 | -$1.93 | -$1.78 | -$1.85 | -$1.69 | -$1.69 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$407.3M | -$309.5M | -$296.1M | -$389.8M | -$373.0M |
| Capital expenditure | -$5.7M | -$4.9M | -$999,000 | -$1.7M | -$4.3M |
| Free cash flow | -$413.1M | -$314.4M | -$297.1M | -$391.5M | -$377.3M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | -$802.5M | $2.7M | $5.4M | $14.4M | $8.7M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $617.6M
- Total assets
- $1.11B
- Total liabilities
- $82.4M
- Total debt
- $31.2M
- Net debt
- -$68.5M
- Shareholders’ equity
- $1.03B
As of Jun 30, 2026 (filed Jul 30, 2026).
Short interest
- Shares sold short
- 7,557,252
- Days to cover
- 9.46
- Change vs previous report
- +0.3%
FINRA short interest, settlement date Sep 15, 2026.